Peter is Director of Research at Tevard Biosciences, where he leads efforts to advance the company’s tRNA-based therapies targeting rare diseases. Since joining Tevard in 2018, he has been instrumental in building research programs that span cardiovascular, neurological, and muscular indications, driving the scientific rigor behind the company’s growing pipeline.
Peter has more than 20 years of experience in research and early-stage drug development. Prior to Tevard, he served as a Research Scientist at the Massachusetts Institute of Technology, where he managed neurotechnology-focused projects and research collaborations. Earlier in his career, Peter held scientific leadership roles at biotechnology companies, including Intellimedix, Zygogen, and Genentech, where he guided programs from concept through IND-enabling studies.
Peter earned his Ph.D. in molecular and cell biology at the University of California, Berkeley, and holds a B.S. from the University of Wisconsin-Madison.